Table of Contents Author Guidelines Submit a Manuscript
International Journal of Dentistry
Volume 2010, Article ID 186018, 10 pages
http://dx.doi.org/10.1155/2010/186018
Review Article

A Review of the Nonsurgical Treatment of Oral Leukoplakia

Department of Oral Surgery, Medicine and Pathology, Dental School, Federal University of Minas Gerais, CEP 31.270-901, Belo Horizonte, Minas Gerais, Brazil

Received 19 June 2009; Revised 26 November 2009; Accepted 13 January 2010

Academic Editor: Paul C. Edwards

Copyright © 2010 Adriana Spinola Ribeiro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. van der Waal and T. Axéll, “Oral leukoplakia: a proposal for uniform reporting,” Oral Oncology, vol. 38, no. 6, pp. 521–526, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Warnakulasuriya, N. W. Johnson, and I. van der Waal, “Nomenclature and classification of potentially malignant disorders of the oral mucosa,” Journal of Oral Pathology and Medicine, vol. 36, no. 10, pp. 575–580, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Axéll, J. J. Pindborg, C. J. Smith, and I. van der Waal, “Oral white lesions with special reference to precancerous and tobacco-related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18–21 1994,” Journal of Oral Pathology and Medicine, vol. 25, no. 2, pp. 49–54, 1996. View at Google Scholar · View at Scopus
  4. I. van der Waal, K. P. Schepman, E. H. van der Meij, and L. E. Smeele, “Oral leukoplakia: a clinicopathological review,” Oral Oncology, vol. 33, no. 5, pp. 291–301, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. B. W. Neville and T. A. Day, “Oral cancer and precancerous lesions,” CA: A Cancer Journal for Clinicians, vol. 52, no. 4, pp. 195–215, 2002. View at Google Scholar · View at Scopus
  6. L. Zhang, K.-J. Cheung Jr., W. L. Lam et al., “Increased genetic damage in oral leukoplakia from high risk sites: potential impact on staging and clinical management,” Cancer, vol. 91, no. 11, pp. 2148–2155, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. K. P. Schepman, E. H. van der Meij, L. E. Smeele, and I. van der Waal, “Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands,” Oral Oncology, vol. 34, no. 4, pp. 270–275, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Saito, C. Sugiura, A. Hirai et al., “Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality,” International Journal of Oral and Maxillofacial Surgery, vol. 30, no. 1, pp. 49–53, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Reibel, “Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics,” Critical Reviews in Oral Biology and Medicine, vol. 14, no. 1, pp. 47–62, 2003. View at Google Scholar · View at Scopus
  10. G. Lodi and S. Porter, “Management of potentially malignant disorders: evidence and critique,” Journal of Oral Pathology and Medicine, vol. 37, no. 2, pp. 63–69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. S. Napier and P. M. Speight, “Natural history of potentially malignant oral lesions and conditions: an overview of the literature,” Journal of Oral Pathology and Medicine, vol. 37, no. 1, pp. 1–10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. I. van der Waal, “Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management,” Oral Oncology, vol. 45, no. 4-5, pp. 317–323, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. I. R. H. Kramer, R. B. Lucas, J. J. Pindborg, and L. H. Sobin, “Definition of leukoplakia and related lesions: an aid to studies on oral precancer,” Oral Surgery Oral Medicine and Oral Pathology, vol. 46, no. 4, pp. 518–539, 1978. View at Google Scholar · View at Scopus
  14. H. A. Al-Drouby, “Oral leukoplakia and cryotherapy,” British Dental Journal, vol. 155, no. 4, pp. 124–125, 1983. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Ishii, K. Fujita, and T. Komori, “Laser surgery as a treatment for oral leukoplakia,” Oral Oncology, vol. 39, no. 8, pp. 759–769, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Ishii, K. Fujita, S. Munemoto, and T. Komori, “Management of oral leukoplakia by laser surgery: relation between recurrence and malignant transformation and clinicopathological features,” Journal of Clinical Laser Medicine and Surgery, vol. 22, no. 1, pp. 27–33, 2004. View at Google Scholar · View at Scopus
  17. G. Fernandes, “Beta-carotene supplementation: friend or foe?” The Journal of Laboratory and Clinical Medicine, vol. 129, no. 3, pp. 285–287, 1997. View at Google Scholar · View at Scopus
  18. S. C. Girod and M. Pfahl, “Retinoid actions and implications for prevention and therapy of oral cancer,” International Journal of Oral and Maxillofacial Surgery, vol. 25, no. 1, pp. 69–73, 1996. View at Google Scholar · View at Scopus
  19. H. Lumerman, P. Freedman, and S. Kerpel, “Oral epithelial dysplasia and the development of invasive squamous cell carcinoma,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and, vol. 79, no. 3, pp. 321–329, 1995. View at Google Scholar · View at Scopus
  20. J. J. Pindborg, O. Jolst, G. Renstrup, and B. Roed-Petersen, “Studies in oral leukoplakia: a preliminary report on the period pervalence of malignant transformation in leukoplakia based on a follow-up study of 248 patients,” The Journal of the American Dental Association, vol. 76, no. 4, pp. 767–771, 1968. View at Google Scholar · View at Scopus
  21. S. Silverman Jr., M. Gorsky, and F. Lozada, “Oral leukoplakia and malignant transformation. A follow-up study of 257 patients,” Cancer, vol. 53, no. 3, pp. 563–568, 1984. View at Google Scholar · View at Scopus
  22. P. Vedtofte, P. Holmstrup, E. Hjorting-Hansen, and J. J. Pindborg, “Surgical treatment of premalignant lesions of the oral mucosa,” International Journal of Oral and Maxillofacial Surgery, vol. 16, no. 6, pp. 656–664, 1987. View at Google Scholar · View at Scopus
  23. M. Gorsky and J. B. Epstein, “The effect of retinoids on premalignant oral lesions: focus on topical therapy,” Cancer, vol. 95, no. 6, pp. 1258–1264, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Hammersley, M. M. Ferguson, and J. S. Rennie, “Topical bleomycin in the treatment of oral leukoplakia: a pilot study,” British Journal of Oral and Maxillofacial Surgery, vol. 23, no. 4, pp. 251–258, 1985. View at Google Scholar · View at Scopus
  25. J. B. Epstein, M. Gorsky, F. L. W. Wong, and A. Millner, “Topical bleomycin for the treatment of dysplastic oral leukoplakia,” Cancer, vol. 83, no. 4, pp. 629–634, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Britton, “Structure and properties of carotenoids in relation to function,” The FASEB Journal, vol. 9, no. 15, pp. 1551–1558, 1995. View at Google Scholar · View at Scopus
  27. S. T. Mayne, “Beta-carotene, carotenoids, and disease prevention in humans,” The FASEB Journal, vol. 10, no. 7, pp. 690–701, 1996. View at Google Scholar · View at Scopus
  28. N. I. Krinsky, “Mechanism of action of biological antioxidants,” Proceedings of the Society for Experimental Biology and Medicine, vol. 200, no. 2, pp. 248–254, 1992. View at Google Scholar · View at Scopus
  29. J. A. Olson, “Benefits and liabilities of vitamin A and carotenoids,” The Journal of Nutrition, vol. 126, supplement 4, pp. 1208S–1212S, 1996. View at Google Scholar · View at Scopus
  30. R. S. Parker, “Absorption, metabolism, and transport of carotenoids,” The FASEB Journal, vol. 10, no. 5, pp. 542–551, 1996. View at Google Scholar · View at Scopus
  31. R. Sankaranarayanan, B. Mathew, C. Varghese et al., “Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment,” Oral Oncology, vol. 33, no. 4, pp. 231–236, 1997. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Liede, J. Hietanen, L. Saxen et al., “Long-term supplementation with alpha-tocopherol and beta-carotene and prevalence of oral mucosal lesions in smokers,” Oral Diseases, vol. 4, no. 2, pp. 78–83, 1998. View at Google Scholar · View at Scopus
  33. G. E. Kaugars, S. Silverman Jr., J. G. L. Lovas et al., “A clinical trial of antioxidant supplements in the treatment of oral leukoplakia,” Oral Surgery, Oral Medicine, Oral Pathology, vol. 78, no. 4, pp. 462–468, 1994. View at Google Scholar · View at Scopus
  34. G. E. Kaugars, S. Silverman Jr., J. G. L. Lovas, J. S. Thompson, R. B. Brandt, and V. N. Singh, “Use of antioxidant supplements in the treatment of human oral leukoplakia: review of the literature and current studies,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 81, no. 1, pp. 5–14, 1996. View at Google Scholar · View at Scopus
  35. J. G. Erhardt, H. Mack, U. Sobeck, and H. K. Biesalski, “β-carotene and α-tocopherol concentration and antioxidant status in buccal mucosal cells and plasma after oral supplementation,” British Journal of Nutrition, vol. 87, no. 5, pp. 471–475, 2002. View at Google Scholar · View at Scopus
  36. K. Malaker, B. J. Anderson, W. A. Beecroft, and D. I. Hodson, “Management of oral mucosal dysplasia with β-carotene retinoic acid: a pilot cross-over study,” Cancer Detection and Prevention, vol. 15, no. 5, pp. 335–340, 1991. View at Google Scholar
  37. S. Toma, S. Benso, E. Albanese et al., “Treatment of oral leukoplakia with beta-carotene,” Oncology, vol. 49, no. 2, pp. 77–81, 1992. View at Google Scholar · View at Scopus
  38. H. S. Garewal, F. L. Meyskens Jr., D. Killen et al., “Response of oral leukoplakia to beta-carotene,” Journal of Clinical Oncology, vol. 8, no. 10, pp. 1715–1720, 1990. View at Google Scholar · View at Scopus
  39. H. S. Garewal, R. V. Katz, F. Meyskens et al., “ß-carotene produces sustained remissions in patients with oral leukoplakia. Results of a multicenter prospective trial,” Archives of Otolaryngology, vol. 125, no. 12, pp. 1305–1310, 1999. View at Google Scholar · View at Scopus
  40. F. M. Painter, “Lycopene: monograph,” Alternative Medicine Review, vol. 8, no. 3, pp. 336–342, 2003. View at Google Scholar
  41. A. V. Rao and S. Agarwal, “Role of antioxidant lycopene in cancer and heart disease,” Journal of the American College of Nutrition, vol. 19, no. 5, pp. 563–569, 2000. View at Google Scholar · View at Scopus
  42. G. Riccioni, B. Mancini, E. Di Ilio, T. Bucciarelli, and N. D'Orazio, “Protective effect of lycopene in cardiovascular disease,” European Review for Medical and Pharmacological Sciences, vol. 12, no. 3, pp. 183–190, 2008. View at Google Scholar · View at Scopus
  43. D. Heber and Q.-Y. Lu, “Overview of mechanisms of action of lycopene,” Experimental Biology and Medicine, vol. 227, no. 10, pp. 920–923, 2002. View at Google Scholar · View at Scopus
  44. T. W.-M. Boileau, A. C. Boileau, and J. W. Erdman Jr., “Bioavailability of all-trans and cis-isomers of lycopene,” Experimental Biology and Medicine, vol. 227, no. 10, pp. 914–919, 2002. View at Google Scholar · View at Scopus
  45. V. Böhm and R. Bitsch, “Intestinal absorption of lycopene from different matrices and interactions to other carotenoids, the lipid status, and the antioxidant capacity of human plasma,” European Journal of Nutrition, vol. 38, no. 3, pp. 118–125, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. P. P. Hoppe, K. Krämer, H. van den Berg, G. Steenge, and T. van Vliet, “Synthetic and tomato-based lycopene have identical bioavailability in humans,” European Journal of Nutrition, vol. 42, no. 5, pp. 272–278, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Nagao, N. Ikeda, S. Warnakulasuriya et al., “Serum antioxidant micronutrients and the risk of oral leukoplakia among Japanese,” Oral Oncology, vol. 36, no. 5, pp. 466–470, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Singh, R. Krishanappa, A. Bagewadi, and V. Keluskar, “Efficacy of oral lycopene in the treatment of oral leukoplakia,” Oral Oncology, vol. 40, no. 6, pp. 591–596, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. R. M. McClain and J. Bausch, “Summary of safety studies conducted with synthetic lycopene,” Regulatory Toxicology and Pharmacology, vol. 37, no. 2, pp. 274–285, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Agarwal and A. V. Rao, “Tomato lycopene and its role in human health and chronic diseases,” Canadian Medical Association Journal, vol. 163, no. 6, pp. 739–744, 2000. View at Google Scholar · View at Scopus
  51. P. M. Bramley, “Is lycopene beneficial to human health?” Phytochemistry, vol. 54, no. 3, pp. 233–236, 2000. View at Publisher · View at Google Scholar · View at Scopus
  52. K. A. Naidu, “Vitamin C in human health and disease is still a mystery? An overview,” Nutrition Journal, vol. 2, pp. 1–10, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. A. B. Kallner, D. Hartmann, and D. H. Hornig, “On the requirements of ascorbic acid in man: steady-state turnover and body pool in smokers,” The American Journal of Clinical Nutrition, vol. 34, no. 7, pp. 1347–1355, 1981. View at Google Scholar · View at Scopus
  54. B. Frei, L. England, and B. N. Ames, “Ascorbate is an outstanding antioxidant in human blood plasma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 16, pp. 6377–6381, 1989. View at Google Scholar · View at Scopus
  55. M. Levine, C. Conry-Cantilena, Y. Wang et al., “Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 8, pp. 3704–3709, 1996. View at Publisher · View at Google Scholar · View at Scopus
  56. V. Tuovinen, M. Väänänen, A. Kullaa, A. Karinpää, H. Markkanen, and E. Kumpusalo, “Oral mucosal changes related to plasma ascorbic acid levels,” Proceedings of the Finnish Dental Society, vol. 88, no. 3-4, pp. 117–122, 1992. View at Google Scholar · View at Scopus
  57. T. J. Barth, J. Zöller, A. Kübler, I. A. Born, and H. Osswald, “Redifferentiation of oral dysplastic mucosa by the application of the antioxidants beta-carotene, α-tocopherol and vitamin C,” International Journal for Vitamin and Nutrition Research, vol. 67, no. 5, pp. 368–376, 1997. View at Google Scholar · View at Scopus
  58. G. W. Burton and M. G. Traber, “Vitamin E: antioxidant activity, biokinetics, and bioavailability,” Annual Review of Nutrition, vol. 10, pp. 357–382, 1990. View at Google Scholar · View at Scopus
  59. K. U. Ingold, V. W. Bowry, R. Stocker, and C. Walling, “Autoxidation of lipids and antioxidation by α-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 1, pp. 45–49, 1993. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Azzi, R. Ricciarelli, and J.-M. Zingg, “Non-antioxidant molecular functions of α-tocopherol (vitamin E),” FEBS Letters, vol. 519, no. 1–3, pp. 8–10, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. J. K. Lodge, “Mass spectrometry approaches for vitamin E research,” Biochemical Society Transactions, vol. 36, no. 5, pp. 1066–1070, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. H. Kamin, “Status of the 10th edition of the recommended dietary allowances—prospects for the future,” The American Journal of Clinical Nutrition, vol. 41, no. 1, pp. 165–170, 1985. View at Google Scholar · View at Scopus
  63. M. G. Traber, D. Rader, R. V. Acuff, R. Ramakrishnan, H. B. Brewer, and H. J. Kayden, “Vitamin E dose-response studies in humans with use of deuterated RRR-α-tocopherol,” The American Journal of Clinical Nutrition, vol. 68, no. 4, pp. 847–853, 1998. View at Google Scholar · View at Scopus
  64. M. K. Horwitt, “Vitamin E: a reexamination,” The American Journal of Clinical Nutrition, vol. 29, no. 5, pp. 569–578, 1976. View at Google Scholar · View at Scopus
  65. E. Herrera and C. Barbas, “Vitamin E: action, metabolism and perspectives,” Journal of Physiology and Biochemistry, vol. 57, no. 2, pp. 43–56, 2001. View at Google Scholar · View at Scopus
  66. S. E. Benner, R. J. Winn, S. M. Lippman et al., “Regression of oral leukoplakia with a-tocopherol: a community clinical oncology program chemoprevention study,” The Journal of the National Cancer Institute, vol. 85, no. 1, pp. 44–47, 1993. View at Google Scholar · View at Scopus
  67. R. D. Azulay and D. R. Azulay, “Atualização em Retinóides,” in Dermatologia, p. 516, Guanabara-Koogan Publishing, Rio de Janeiro, Brazil, 2nd edition, 1999. View at Google Scholar
  68. J. A. Olson and N. I. Krinsky, “Introduction: the colorful, fascinating world of the carotenoids: important physiologic modulators,” The FASEB Journal, vol. 9, no. 15, pp. 1547–1550, 1995. View at Google Scholar · View at Scopus
  69. M. David, E. Hodak, and N. J. Lowe, “Adverse effects of retinoids,” Medical Toxicology and Adverse Drug Experience, vol. 3, no. 4, pp. 273–288, 1988. View at Google Scholar · View at Scopus
  70. J. A. Olson, “Carotenoids and human health,” Archivos Latinoamericanos de Nutricion, vol. 49, no. 3, supplement 1, pp. 7S–11S, 1999. View at Google Scholar · View at Scopus
  71. I. W. Dimery, W. K. Hong, J. J. Lee et al., “Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity,” Annals of Oncology, vol. 8, no. 1, pp. 85–89, 1997. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Piattelli, M. Fioroni, A. Santinelli, and C. Rubini, “bcl-2 expression and apoptotic bodies in 13-cis-retinoic acid (isotretinoin)-topically treated oral leukoplakia: a pilot study,” Oral Oncology, vol. 35, no. 3, pp. 314–320, 1999. View at Publisher · View at Google Scholar · View at Scopus
  73. J. P. Shah, E. W. Strong, J. J. DeCosse, L. Itri, and P. Sellers, “Effect of retinoids on oral leukoplakia,” The American Journal of Surgery, vol. 146, no. 4, pp. 466–470, 1983. View at Google Scholar · View at Scopus
  74. H. F. Stich, A. P. Hornby, B. Mathew, R. Sankaranarayanan, and M. Krishnan Nair, “Response of oral leukoplakias to the administration of vitamin A,” Cancer Letters, vol. 40, no. 1, pp. 93–101, 1988. View at Google Scholar · View at Scopus
  75. H. F. Stich, M. P. Rosin, A. P. Hornby, B. Mathew, R. Sankaranarayanan, and M. Krishnan Nair, “Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with β-carotene and with β-carotene plus vitamin A,” International Journal of Cancer, vol. 42, no. 2, pp. 195–199, 1988. View at Google Scholar · View at Scopus
  76. S. Toma, P. E. Mangiante, G. Margarino, G. Nicolo, and R. Palumbo, “Progressive 13-cis-retinoic acid dosage in the treatment of oral leukoplakia,” European Journal of Cancer B, vol. 28, no. 2, pp. 121–123, 1992. View at Publisher · View at Google Scholar · View at Scopus
  77. S. M. Lippman, J. G. Batsakis, B. B. Toth et al., “Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis,” The New England Journal of Medicine, vol. 328, no. 1, pp. 15–20, 1993. View at Publisher · View at Google Scholar · View at Scopus
  78. J. B. Epstein and M. Gorsky, “Topical application of vitamin A to oral leukoplakia: a clinical case series,” Cancer, vol. 86, no. 6, pp. 921–927, 1999. View at Publisher · View at Google Scholar · View at Scopus
  79. F. Femiano, F. Gombos, C. Scully, C. Battista, G. Belnome, and V. Esposito, “Oral leukoplakia: open trial of topical therapy with calcipotriol compared with tretinoin,” International Journal of Oral and Maxillofacial Surgery, vol. 30, no. 5, pp. 402–406, 2001. View at Publisher · View at Google Scholar · View at Scopus
  80. G. A. Scardina, F. Carini, E. Maresi, V. Valenza, and P. Messina, “Evaluation of the clinical and histological effectiveness of isotretinoin in the therapy of oral leukoplakia—ten years of experience: is management still up to date and effective?” Methods and Findings in Experimental and Clinical Pharmacology, vol. 28, no. 2, pp. 115–119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. M. B. Sporn and D. L. Newton, “Chemoprevention of cancer with retinoids,” Federation Proceedings, vol. 38, no. 11, pp. 2528–2534, 1979. View at Google Scholar · View at Scopus
  82. R. C. Moon, H. J. Thompson, P. J. Becci et al., “N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat,” Cancer Research, vol. 39, no. 4, pp. 1339–1346, 1979. View at Google Scholar · View at Scopus
  83. J. D. Paulson, J. W. Oldham, R. F. Preston, and D. Newman, “Lack of genotoxicity of the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide,” Fundamental and Applied Toxicology, vol. 5, no. 1, pp. 144–150, 1985. View at Google Scholar · View at Scopus
  84. F. Chiesa, N. Tradati, R. Grigolato et al., “Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results,” International Journal of Cancer, vol. 115, no. 4, pp. 625–629, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. R. Torrisi and A. Decensi, “Fenretinide and cancer prevention,” Current Oncology Reports, vol. 2, no. 3, pp. 263–270, 2000. View at Google Scholar · View at Scopus
  86. F. Chiesa, N. Tradati, M. Marazza et al., “Fenretinide (4-HPR) in chemoprevention of oral leukoplakia,” Journal of Cellular Biochemistry, vol. 52, supplement 17, pp. 255–261, 1993. View at Google Scholar · View at Scopus
  87. N. Tradati, F. Chiesa, N. Rossi et al., “Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR),” Cancer Letters, vol. 76, no. 2-3, pp. 109–111, 1994. View at Google Scholar · View at Scopus
  88. S. M. Lippman, J. J. Lee, J. W. Martin et al., “Fenretinide activity in retinoid-resistant oral leukoplakia,” Clinical Cancer Research, vol. 12, no. 10, pp. 3109–3114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. J. M. Bennett and S. D. Reich, “Bleomycin,” Annals of Internal Medicine, vol. 90, no. 6, pp. 945–948, 1979. View at Google Scholar · View at Scopus
  90. A. Siéron, G. Namyslowski, M. Misiolek, M. Adamek, and A. Kawczyk-Krupka, “Photodynamic therapy of premalignant lesions and local recurrence of laryngeal and hypopharyngeal cancers,” European Archives of Oto-Rhino-Laryngology, vol. 258, no. 7, pp. 349–352, 2001. View at Publisher · View at Google Scholar · View at Scopus
  91. A. C. Kübler, “Photodynamic therapy,” Medical Laser Application, vol. 20, no. 1, pp. 37–45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. K. Konopka and T. Goslinski, “Photodynamic therapy in dentistry,” Journal of Dental Research, vol. 86, no. 8, pp. 694–707, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. C. J. Kelty, N. J. Brown, M. W. R. Reed, and R. Ackroyd, “The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis,” Photochemical and Photobiological Sciences, vol. 1, no. 3, pp. 158–168, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. J. M. Zakrzewska, V. Lopes, P. Speight, and C. Hopper, “Proliferative verrucous leukoplakia a report of ten cases,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 82, no. 4, pp. 396–401, 1996. View at Google Scholar · View at Scopus
  95. A. Kübler, T. Haase, M. Rheinwald, T. Barth, and J. Mühling, “Treatment of oral leukoplakia by topical application of 5-aminolevulinic acid,” International Journal of Oral and Maxillofacial Surgery, vol. 27, no. 6, pp. 466–469, 1998. View at Google Scholar · View at Scopus
  96. A. Sieroń, M. Adamek, A. Kawczyk-Krupka, S. Mazur, and L. Ilewicz, “Photodynamic therapy (PDT) using topically applied δ-aminolevulinic acid (ALA) for the treatment of oral leukoplakia,” Journal of Oral Pathology and Medicine, vol. 32, no. 6, pp. 330–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. H.-M. Chen, C.-H. Yu, P.-C. Tu, C.-Y. Yeh, T. Tsai, and C.-P. Chiang, “Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy,” Lasers in Surgery and Medicine, vol. 37, no. 2, pp. 114–122, 2005. View at Publisher · View at Google Scholar · View at Scopus